Axsome Advances Adolescent ADHD Study as Investors Await Solriamfetol Data
at www.tipranks.com (Fri, 6-Nov 11:33 AM)
Axsome Advances Pediatric ADHD Study as Solriamfetol Trial Recruits
at www.tipranks.com (Fri, 6-Nov 11:32 AM)
Axsome Advances Solriamfetol Safety Study in Children With ADHD
at www.tipranks.com (Fri, 6-Nov 11:31 AM)
Axsome Therapeutics (AXSM) Receives a New Rating from B. Riley Securities
at www.tipranks.com (Tue, 3-Nov 8:45 AM)
Axsome Therapeutics (AXSM) Gets a Buy from Cantor Fitzgerald
at www.tipranks.com (Tue, 3-Nov 7:59 AM)
Axsome Therapeutics (AXSM) Receives a Buy from Wells Fargo
at www.tipranks.com (Tue, 3-Nov 7:56 AM)
Axsome’s Q3 run rate tops $1 billion as Auvelity demand and Alzheimer’s agitation starts accelerate
Market Chameleon (Mon, 2-Nov 7:32 AM)
Axsome’s 46% Revenue Surge Underscores Expanding CNS Franchise and Pipeline Momentum
Market Chameleon (Mon, 10-Aug 7:30 AM)
